Hunza Eats - Journal
Shilajit and Testosterone: What the Actual Clinical Trials Found
Of everything shilajit is sold for, "natural testosterone support" is the claim that travels furthest and fastest, repeated across supplement brand pages, men's health publishers, and fitness forums with a confidence that outpaces what the underlying research actually shows. That research is real, and it is more specific and more limited than most of the marketing built on top of it. It is anchored almost entirely to two small human trials, one in healthy men and one in men with fertility concerns, both run for 90 days. This article walks through exactly what each one found, in the researchers' own reported numbers, not in the rounded-up version that tends to survive by the time it reaches a product page.
The Science
The most frequently cited shilajit-testosterone trial recruited healthy men aged 45 to 55 and ran a randomized, double-blind, placebo-controlled design, the strongest type of human trial design, for 90 consecutive days. Participants took 250mg of purified shilajit twice daily (500mg/day total). A separate, differently designed trial looked at men with oligospermia (low sperm count) rather than healthy men, using a lower dose without a placebo group.
| Trial | Population and design | Reported result | Source |
|---|---|---|---|
| Pandit et al., 2016 | Healthy men, 45-55, randomized double-blind placebo-controlled, 90 days, 250mg twice daily | Total testosterone rose 20.45% (398.8 to 474.91 ng/dL) versus placebo; free testosterone rose 19.14%; DHEAS also rose significantly; LH and FSH remained well maintained | PubMed 26395129 |
| Oligospermia fertility trial | Men with low sperm count, open-label, no control group, 90 days, 100mg twice daily (200mg/day) | Serum testosterone rose 23.5% (4.85 to 5.99 ng/mL); total sperm count rose 61.4%; normal sperm morphology rose 18.9%; FSH rose 9.8% | PubMed 20078516 |
The chart below shows the Pandit healthy-men trial's three reported hormone changes side by side, since this is the trial most often cited as shilajit's flagship testosterone evidence.
Source: Pandit, S. et al., Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers, PubMed 26395129. Bar heights scaled relative to a 30% maximum for visual comparison only.
Three honest caveats belong directly next to these numbers, because they materially change how confidently the results should be read. First, the Pandit trial was funded by the manufacturer of the shilajit preparation being tested, a real conflict-of-interest limitation the study itself discloses. Second, testosterone actually declined in the placebo group over the 90 days, which may have widened the apparent gap between groups beyond what shilajit alone produced. Third, the oligospermia trial had no placebo or control group at all, so some portion of the reported improvement could reflect natural variation, other lifestyle changes over 90 days, or a placebo-type effect rather than shilajit's direct action. Neither trial has been independently replicated by a separate research team at the time of this writing, which researchers reviewing this evidence base consistently flag as the main reason larger, independent, longer-duration trials are still needed before shilajit's testosterone effects can be called well established.
The Source
Both trials used purified, standardized shilajit extract, not raw resin scraped straight from rock. That distinction matters for anyone trying to relate these results to a specific product: a study result for a purified, tested 250mg dose does not automatically transfer to an unpurified, untested product sold under the same name. Reputable brands filter and lab-test their shilajit specifically to try to match the composition used in trials like these; the honest fact is that consistency and purity vary meaningfully brand to brand, and a certificate of analysis is the only way to know what you are actually taking. HunzaEats' Shilajit Choco Bites deliver a fixed, known 0.05g of shilajit per bite, giving a transparent starting point for anyone building toward the dose ranges used in this research.
The Preparation
Anyone specifically interested in the testosterone research should understand that the trial doses (200-500mg/day) sit within, not at the extreme end of, the general safe dosage range most guides cite (250-1,000mg/day). Reaching a trial-comparable dose does not require maximizing intake; it means building gradually from a low starting dose (100-150mg/day for the first week or two) up toward the 250-500mg/day range used in the studies above, generally split into two doses per day as both trials did, taken with food or dissolved in warm water or milk.
Comprehensive Precautions and Safety
- This is not a substitute for medical evaluation of low testosterone. Anyone with symptoms of clinically low testosterone should see a doctor for proper bloodwork and diagnosis rather than self-treating with a supplement.
- Pregnancy and breastfeeding: Not applicable to this specific benefit, but shilajit should be avoided in these populations regardless due to insufficient safety data.
- Existing conditions: Men with hormone-sensitive conditions, or any condition affected by testosterone levels, should talk to a physician before using a product marketed for this purpose.
- Drug interactions: Anyone on hormone therapy, blood sugar-lowering medications, or thyroid medications should confirm safety with a doctor first.
- Contamination risk: Only use a product with a current, brand-specific third-party lab report for heavy metals; this applies with particular weight to a product being taken specifically for a hormonal benefit.
- Evidence-honesty: Treat the testosterone claim as a promising but preliminary early finding, not an established, guaranteed effect. No regulator has approved shilajit as a treatment for low testosterone.
| Region | Regulatory framework | What it means for a testosterone claim |
|---|---|---|
| United States | FDA, under DSHEA | "Supports healthy testosterone levels" is a structure/function claim, legally requiring the disclaimer that it has not been evaluated by the FDA. A direct claim to treat low testosterone as a medical condition would be illegal for a supplement. |
| United Kingdom | MHRA, Traditional Herbal Registration (THR) scheme | A THR-registered product may carry only very specific, pre-approved traditional-use wording; shilajit sold as a general food supplement in the UK cannot legally make a medical testosterone claim at all. |
| Canada | Health Canada, Natural Health Products Regulations (NHPR) | Any specific health claim, including a hormonal one, requires an NPN and Health Canada's review of the supporting evidence before it can legally appear on a Canadian product label. |
Educational disclaimer: This article is for general educational purposes only. It is not medical advice, and the statements here have not been evaluated by the FDA, Health Canada, or the MHRA. Shilajit and any product containing it is not intended to diagnose, treat, cure, or prevent any disease, including low testosterone. Speak with a qualified healthcare provider before starting shilajit, especially if you are managing a hormonal or reproductive health condition or taking prescription medication.
Sources
- Pandit, S. et al. Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. PubMed 26395129.
- Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. PubMed 20078516.
- Examine.com, Shilajit research breakdown and dosage summary.
- U.S. FDA, Questions and Answers on Dietary Supplements (DSHEA framework).
- GOV.UK, Apply for a Traditional Herbal Registration (THR).
- Health Canada, Natural Health Product Licensing Bulletin (NPN).
This information is provided for general interest only and has not been evaluated by any regulatory authority. Hunza Eats products are not intended to diagnose, treat, cure, or prevent any disease, and are not a substitute for professional medical advice. Please consult your doctor before making changes to your diet or health routine.
Our Bestsellers
More From The Journal
Advertisement by Google